Catherine M Bollard1, Stephen Gottschalk, Vicky Torrano, Oumar Diouf, Stephanie Ku, Yasmin Hazrat, George Carrum, Carlos Ramos, Luis Fayad, Elizabeth J Shpall, Barbara Pro, Hao Liu, Meng-Fen Wu, Daniel Lee, Andrea M Sheehan, Youli Zu, Adrian P Gee, Malcolm K Brenner, Helen E Heslop, Cliona M Rooney. 1. Catherine M. Bollard, Stephen Gottschalk, Vicky Torrano, Oumar Diouf, Stephanie Ku, Yasmin Hazrat, George Carrum, Carlos Ramos, Hao Liu, Meng-Fen Wu, Andrea M. Sheehan, Adrian P. Gee, Malcolm K. Brenner, Helen E. Heslop, and Cliona M. Rooney, Baylor College of Medicine and Texas Children's Hospital; Catherine M. Bollard, Stephen Gottschalk, Vicky Torrano, Oumar Diouf, Stephanie Ku, Yasmin Hazrat, George Carrum, Carlos Ramos, Hao Liu, Meng-Fen Wu, Daniel Lee, Andrea M. Sheehan, Youli Zu, Adrian P. Gee, Malcolm K. Brenner, Helen E. Heslop, and Cliona M. Rooney, Methodist Hospital; Luis Fayad, Elizabeth J. Shpall, and Barbara Pro, MD Anderson Cancer Center, Houston, TX; and Daniel Lee and Youli Zu, Weill Medical College of Cornell University, New York, NY.
Abstract
PURPOSE: Tumor cells from approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2, which represent attractive targets for immunotherapy. Because T cells specific for these antigens are present with low frequency and may be rendered anergic by the tumors that express them, we expanded LMP-cytotoxic T lymphocytes (CTLs) from patients with lymphoma using autologous dendritic cells and EBV-transformed B-lymphoblastoid cell lines transduced with an adenoviral vector expressing either LMP2 alone (n = 17) or both LMP2 and ΔLMP1 (n = 33). PATIENTS AND METHODS: These genetically modified antigen-presenting cells expanded CTLs that were enriched for specificity against type II latency LMP antigens. When infused into 50 patients with EBV-associated lymphoma, the expanded CTLs did not produce infusional toxicities. RESULTS: Twenty-eight of 29 high-risk or multiple-relapse patients receiving LMP-CTLs as adjuvant therapy remained in remission at a median of 3.1 years after CTL infusion. None subsequently died as a result of lymphoma, but nine succumbed to complications associated with extensive prior chemoradiotherapy, including myocardial infarction and secondary malignancies. Of 21 patients with relapsed or resistant disease at the time of CTL infusion, 13 had clinical responses, including 11 complete responses. T cells specific for LMP as well as nonviral tumor-associated antigens (epitope spreading) could be detected in the peripheral blood within 2 months after CTL infusion, but this evidence for epitope spreading was seen only in patients achieving clinical responses. CONCLUSION: Autologous T cells directed to the LMP2 or LMP1 and LMP2 antigens can induce durable complete responses without significant toxicity. Their earlier use in the disease course may reduce delayed treatment-related mortality.
PURPOSE:Tumor cells from approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2, which represent attractive targets for immunotherapy. Because T cells specific for these antigens are present with low frequency and may be rendered anergic by the tumors that express them, we expanded LMP-cytotoxic T lymphocytes (CTLs) from patients with lymphoma using autologous dendritic cells and EBV-transformed B-lymphoblastoid cell lines transduced with an adenoviral vector expressing either LMP2 alone (n = 17) or both LMP2 and ΔLMP1 (n = 33). PATIENTS AND METHODS: These genetically modified antigen-presenting cells expanded CTLs that were enriched for specificity against type II latency LMP antigens. When infused into 50 patients with EBV-associated lymphoma, the expanded CTLs did not produce infusional toxicities. RESULTS: Twenty-eight of 29 high-risk or multiple-relapse patients receiving LMP-CTLs as adjuvant therapy remained in remission at a median of 3.1 years after CTL infusion. None subsequently died as a result of lymphoma, but nine succumbed to complications associated with extensive prior chemoradiotherapy, including myocardial infarction and secondary malignancies. Of 21 patients with relapsed or resistant disease at the time of CTL infusion, 13 had clinical responses, including 11 complete responses. T cells specific for LMP as well as nonviral tumor-associated antigens (epitope spreading) could be detected in the peripheral blood within 2 months after CTL infusion, but this evidence for epitope spreading was seen only in patients achieving clinical responses. CONCLUSION: Autologous T cells directed to the LMP2 or LMP1 and LMP2 antigens can induce durable complete responses without significant toxicity. Their earlier use in the disease course may reduce delayed treatment-related mortality.
Authors: James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg Journal: Blood Date: 2011-12-08 Impact factor: 22.113
Authors: Ekaterina Doubrovina; Banu Oflaz-Sozmen; Susan E Prockop; Nancy A Kernan; Sara Abramson; Julie Teruya-Feldstein; Cyrus Hedvat; Joanne F Chou; Glenn Heller; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Diane George; Ann Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Andromachi Scaradavou; Trudy N Small; Ramzi Khalaf; James W Young; Richard J O'Reilly Journal: Blood Date: 2011-12-02 Impact factor: 22.113
Authors: Vanya Icheva; Simone Kayser; Daniel Wolff; Sebastian Tuve; Christina Kyzirakos; Wolfgang Bethge; Johann Greil; Michael H Albert; Wolfgang Schwinger; Michaela Nathrath; Michael Schumm; Stefan Stevanovic; Rupert Handgretinger; Peter Lang; Tobias Feuchtinger Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: W K Chia; W-W Wang; M Teo; W M Tai; W T Lim; E H Tan; S S Leong; L Sun; J J Chen; S Gottschalk; H C Toh Journal: Ann Oncol Date: 2011-08-04 Impact factor: 32.976
Authors: Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard Journal: Clin Cancer Res Date: 2011-09-09 Impact factor: 12.531
Authors: Barbara Savoldo; Carlos Almeida Ramos; Enli Liu; Martha P Mims; Michael J Keating; George Carrum; Rammurti T Kamble; Catherine M Bollard; Adrian P Gee; Zhuyong Mei; Hao Liu; Bambi Grilley; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti Journal: J Clin Invest Date: 2011-04-11 Impact factor: 14.808
Authors: Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June Journal: N Engl J Med Date: 2013-03-25 Impact factor: 91.245
Authors: M R Luskin; D S Heil; K S Tan; S Choi; E A Stadtmauer; S J Schuster; D L Porter; R H Vonderheide; A Bagg; D F Heitjan; D E Tsai; R Reshef Journal: Am J Transplant Date: 2015-05-18 Impact factor: 8.086
Authors: David M Weinstock; Riccardo Dalla-Favera; Randy D Gascoyne; John P Leonard; Ronald Levy; Izidore S Lossos; Ari M Melnick; Grzegorz S Nowakowski; Oliver W Press; Kerry J Savage; Margaret A Shipp; Louis M Staudt Journal: Blood Date: 2015-03-26 Impact factor: 22.113
Authors: Bradley M Haverkos; Ying Huang; Alejandro Gru; Preeti Pancholi; Aharon G Freud; Anjali Mishra; Amy S Ruppert; Robert A Baiocchi; Pierluigi Porcu Journal: Int J Cancer Date: 2017-04-15 Impact factor: 7.396